It has been shown that the use of BAY11-7082, a selected inhibitor of the NF-κB pathway, inhibits anti-inflammatory macrophage phenotype and reduces the invasiveness of bladder cancer cells by increasing the expression of miR30a [166]. This evidence concerns the gene NFKB1 and urinary bladder carcinoma.